Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study
- 469 Downloads
The response of colorectal liver metastases to the cytotoxic agent irinotecan varies widely. Attempts to correlate tumour metabolism with response have been mixed. This study investigated the hepatic metabolism of irinotecan as a potential predictor of tumour response to irinotecan-eluting beads (DEBIRI).
Ten patients with colorectal liver metastases were treated with 200 mg irinotecan (as DEBIRI) as part of the PARAGON II study. Hepatic expression of key metabolising enzymes was measured using mass spectrometry-based proteomics. Serum drug concentrations and hepatic irinotecan metabolism were characterised and correlated with tumour response.
Serum concentrations of irinotecan metabolites did not correlate with hepatic metabolism or pathological response. There was a strong correlation between hepatic CES-2 expression and activation of irinotecan (r2 = 0.96, p < 0.001). Patients with a UGT1A1*28 6/7 SNP showed no difference in drug metabolism or pathological response. Hepatic CES-2 mediated activation of irinotecan clearly correlated with tumour replacement by fibrosis (r2 = 0.54, p = 0.01).
This study provides the first evidence that hepatic activation of irinotecan predicts tumour response. Delivery of liver-targeted irinotecan to normal liver tissue rather than tumour may be a more rational approach to maximise response.
KeywordsDEBIRI Irinotecan Carboxylesterase Liver Colorectal Metastases
- 5.Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18(2):299–304PubMedCrossRefGoogle Scholar
- 7.Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007–1016PubMedCrossRefGoogle Scholar
- 8.Nordlinger B (2012) EORTC liver metastases intergroup randomized phase III study 40983: long-term survival results. J Clin Oncol 30, abstr 3508Google Scholar
- 13.Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA (2011) The effect of St John’s Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol 57(1):86–93PubMedCrossRefGoogle Scholar
- 16.Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ et al (2007) Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 370(9582):143–152PubMedCrossRefGoogle Scholar
- 17.Koopman M, Knijn N, Richman S, Seymour M, Quirke P, van Tinteren H et al (2009) 6003 The correlation between Topoisomerase-I (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG). Eur J Cancer Suppl 7(2):321–322CrossRefGoogle Scholar
- 18.Jones RP (2012) Neoadjuvant treatment of colorectal liver metastases (CRLM) with drug eluting beads trans-arterial chemoembolization (DEBIRI-TACE): a multi-institute phase II study in resectable metastases. J Clin Oncol 30, abstr 3613Google Scholar
- 19.Wyatt J, Hübscher S, and Goldin R (2012) Standards and datasets for reporting cancer; liver resection specimens, 2nd edn. Royal College of Pathologists, LondonGoogle Scholar
- 20.Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V et al (2007) Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18(2):299–304PubMedCrossRefGoogle Scholar
- 22.Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P (1991) A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques 11(3):298–300, 302Google Scholar
- 24.Fda US (2001) Guidance for industry: bioanalytical method validation. CDER, Rockville, MDGoogle Scholar
- 25.Martin RCG, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M et al (2010) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 18(1):192–198PubMedCrossRefGoogle Scholar
- 26.Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P et al (2012) Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32(4):1387–1395PubMedGoogle Scholar
- 39.Cecchin E, Corona G, Masier S, Biason P, Cattarossi G, Frustaci S et al (2005) Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res 11(19 Pt 1):6901–6907PubMedCrossRefGoogle Scholar